Copyright © 2016

Aridis Pharmaceuticals, Inc.

5941 Optical Court, San Jose, CA 95138

Phone: 408-385-1742

Site Map

Privacy Policy

Financial Conflict of Interest Policy

Back to top

Previous page

Scientific Advisory Board

Roger Pomerantz, M.D.

Chairman

Dr. Pomerantz is currently President, Chief Executive Officer, and Chairman of the Board of Directors of Seres Therapeutics, Inc. ("Seres"). He was formerly Worldwide Head of Licensing & Acquisitions, Senior Vice President at Merck & Co., Inc. where he oversaw all licensing and acquisitions at Merck Research Laboratories. Previously, he served as Senior Vice President and Global Franchise Head of Infectious Diseases at Merck. Prior to joining Merck, Roger was Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals, responsible for all anti-infective agents worldwide. He has been responsible for leading the development of 8 approved drugs for HIV, HCV and MDR-TB. He received his B.A. in Biochemistry at the Johns Hopkins University and his M.D. at the Johns Hopkins School of Medicine. His post-doctoral research training in molecular retrovirology was obtained at both Harvard Medical School and the Whitehead Institute of the Massachusetts Institute of Technology (MIT), in the laboratory of Nobel Laureate Dr. David Baltimore. Dr. Pomerantz also served as the Chief Resident at the Massachusetts General Hospital.


Harry Greenberg, M.D.

Dr. Greenberg is currently the Joseph D. Grant Professor of Medicine and Microbiology and Immunology and the Senior Associate Dean for Research and Training at Stanford University School of Medicine.  He was formerly Sr. Vice President and Chief Scientific Officer at Aviron.  He is a virologist and a world leader in enteric diseases, as well as one of the inventors of bovine rotavirus vaccine™.  An expert in vaccine safety and efficacy, he serves as a member of the CDC’s Advisory Committee on Immunization Practices (ACIP) and as chairman of the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC).  He has published more than 350 scientific papers, served on the editorial boards of a number of journals and is currently an editor of the Journal of Virology.  Dr. Greenberg is a member or fellow of a variety of scholarly societies, including the ASCI, AAP, ASV and the AAAS.  Dr. Greenberg received his M.D. from Columbia College of Physicians and Surgeons in 1970.


Steven Opal, M.D.

Dr. Opal served as chief of the infectious disease division at Memorial Hospital of Rhode Island and has served as the principal investigator for numerous, worldwide, multi-center trials of adjuvant agents for severe sepsis.  He has also served on numerous data safety monitoring boards is an internationally recognized key opinion leader in sepsis and pneumonia.  Dr. Opal has written more than 150 peer-reviewed research articles and has edited several academic research journals, as well as three textbooks on infectious diseases, endotoxin-mediated diseases and septic shock.

John S. Patton, Ph.D.

Dr. Patton was Co-Founder and served as the former Chief Scientific Officer of Nektar Therapeutics.  A renowned expert in the pulmonary delivery of peptides and proteins, Dr. Patton co-founded Inhale Therapeutic Systems and led the drug delivery group at Genentech, where he demonstrated the feasibility of systemic delivery of large molecules through the lungs.  Prior to joining Genentech, Dr. Patton was a tenured professor at the University of Georgia.  He received his Ph.D. in biology from the University of California, San Diego, and held post-doctoral positions in biomedicine at Harvard Medical School and the University of Lund in Sweden.


Jerry Pier, Ph.D.

Dr. Pier is Professor of Medicine, Microbiology and Molecular Genetics at Brigham and Women’s Hospital, Harvard Medical School.  He is a molecular microbiologist and a recognized expert on Pseudomonas and Staphylococci and is the inventor of human anti-Pseudomonas aeruginosa monoclonal antibodies (Aerucin™) and a number of vaccines and antibody therapeutics against Pseudomonas and Staphylococci.  He has published more than 150 publications on pathogen host interactions, bacterial virulence factors, cystic fibrosis and treatment for Pseudomonas infections.  Dr. Pier is also the senior editor of the immunology textbook Immunology, infection and Immunity.


Arnold Smith, M.D.

Dr. Smith is Professor of Pediatrics in the Department of Pathobiology, University of Washington and a Member of the Seattle Biomedical Research Institute.  He spent more than 15 years developing better antibiotic treatment for children with cystic fibrosis at Children's Hospital and Regional Medical Center in Seattle.  Dr. Smith performed the first clinical trials demonstrating efficacy of inhaled tobramycin against CF lung infections.  A pediatric infectious disease expert, Dr. Smith spent the first two decades of his academic career at Harvard Medical School and then at University of Missouri School of Medicine as part of teams that developed a vaccine to prevent life-threatening Haemophilus influenzae infections.  He was Professor and Chair, Department of Molecular Microbiology and Immunology at University of Missouri Medical School and Acting Chief of the Division of Infectious Diseases of the Children’s Hospital Medical Center at Harvard Medical School.

PHARMACEUTICALS

Breakthrough Therapies for

Antibiotic Resistant Infections

Aridis